CNAT Insider Trading Activity and SEC Form 4 Filings
CNAT insider trading summary
No open-market insider purchases or sales of Conatus Pharmaceuticals Inc. (CNAT) have been reported on SEC Form 4 in the past 12 months.
Latest CNAT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 8, 2015 | Daniel L Kisner | Director | Buy | $23K (4,000 @ $5.75) |
| Jul 30, 2013 | Luke Evnin | 10% Owner | Buy | $1.8M (165,265 @ $11.00) |
| Jul 30, 2013 | Advent Venture Partners LLP | 10% Owner | Sell | $6K (535 @ $11.00) |
| Jul 30, 2013 | Ansbert Gadicke | 10% Owner | Buy | $1.8M (165,265 @ $11.00) |
| Jul 30, 2013 | Vaughn M Kailian | 10% Owner | Buy | $1.8M (165,265 @ $11.00) |
| Jul 30, 2013 | Louis P Lacasse | Director | Buy | $1.4M (123,950 @ $11.00) |
| Jul 30, 2013 | Todd Foley | 10% Owner | Buy | $1.8M (165,265 @ $11.00) |
| Jul 30, 2013 | Advent Venture Partners LLP | 10% Owner | Buy | $2.1M (190,054 @ $11.00) |
| Jul 30, 2013 | Steven J Mento | President, CEO & Director | Buy | $152K (13,800 @ $11.00) |
| Jul 30, 2013 | Vort John Vander | 10% Owner | Buy | $1.8M (165,265 @ $11.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.